1. Search Result
Search Result
Results for "

MTAP

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148419

    Histone Methyltransferase Cancer
    TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research .
    TNG908
  • HY-156680

    Histone Methyltransferase Cancer
    TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers .
    TNG-462
  • HY-112130
    AGI-24512
    1 Publications Verification

    Methionine Adenosyltransferase (MAT) Cancer
    AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer .
    AGI-24512
  • HY-101496
    MT-DADMe-ImmA
    2 Publications Verification

    MTDIA; Methylthio-DADMe-Immucillin A

    Others Cancer
    MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.
    MT-DADMe-ImmA
  • HY-153390

    Histone Methyltransferase Cancer
    AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP .
    AMG-193
  • HY-RS08749

    Small Interfering RNA (siRNA) Others

    MTAP Human Pre-designed siRNA Set A contains three designed siRNAs for MTAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MTAP Human Pre-designed siRNA Set A
    MTAP Human Pre-designed siRNA Set A
  • HY-155149

    Methionine Adenosyltransferase (MAT) Cancer
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP -/- cell line) .
    MAT2A-IN-12
  • HY-162783

    Histone Methyltransferase Cancer
    AZ-PRMT5i-1 (Compound 28) is an effective and orally active MTAP-selective PRMT5 inhibitor. AZ-PRMT5i-1 also demonstrates MTA cooperativity and exhibits both in vitro and in vivo antitumor activities, and can be used to study MTAP-deficient cancers .
    AZ-PRMT5i-1
  • HY-162010

    Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research .
    MAT2A-IN-13
  • HY-112129

    Methionine Adenosyltransferase (MAT) Cancer
    AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
    AGI-25696
  • HY-162353

    Methionine Adenosyltransferase (MAT) Cancer
    AZ9567 is a potent MAT2A inhibitor. AZ9567 exhibits antiproliferative activity against MTAP KO HCT116 cells with a pIC50 of 8.9 .
    AZ'9567
  • HY-139611C

    Histone Methyltransferase Cancer
    MRTX-1719 hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells .
    MRTX-1719 hydrochloride
  • HY-16933
    L-Alanosine
    1 Publications Verification

    NSC-153353; SDX-102

    Antibiotic Infection Cancer
    L-Alanosine (NSC-153353), an antibiotic from Streptomyces alanosinicus, has antineoplastic activity. L-Alanosine (NSC-153353) inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate. L-Alanosine (NSC-153353) blocks the common de novo purine biosynthesis pathway and, thereby, inhibits tumor cells with MTAP deficiency .
    L-Alanosine
  • HY-144181

    Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
    MAT2A-IN-5
  • HY-144184

    Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
    MAT2A-IN-6
  • HY-144185

    Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
    MAT2A-IN-7
  • HY-142930

    Somatostatin Receptor Cancer
    MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
    MAT2A-IN-3
  • HY-142929

    Somatostatin Receptor Cancer
    MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
    MAT2A-IN-2
  • HY-142928

    Somatostatin Receptor Cancer
    MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
    MAT2A-IN-1
  • HY-138684

    Histone Methyltransferase Cancer
    MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768
  • HY-138684A

    Histone Methyltransferase Cancer
    MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768 hydrochloride
  • HY-163799

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC50 of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .
    PRMT5-MTA-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: